4 active not recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Metastatic Soft-tissue Sarcoma: new trials by email Literature Review of Metastatic Soft-tissue Sarcoma trials Research Report on Metastatic Soft-tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas Pazopanib, HDM201 - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Centre Leon Berard | 47 | 2022-04-15 | 2026-06-22 |
| Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma Bintrafusp alfa, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 2 | Active not recruiting | Institut Bergonié | 80 | 2022-03-01 | 2026-07-24 |
| Lurbinectedin + Doxorubicin In Leiomyosarcoma Lurbinectedin, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Massachusetts General Hospital | 62 | 2022-02-04 | 2026-08-27 |
| Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma Cabozantinib, Nivolumab, Ipilimumab - Metastatic Soft-tissue Sarcoma | Phase 2 | Active not recruiting | Washington University School of Medicine | 105 | 2021-01-05 | 2025-11-12 |
Sarcoma (4) · Neoplasm Metastasis (1) · Tertiary Lymphoid Structures (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
Doxorubicin (2) · Ipilimumab (1) · Nivolumab (1) · PM 01183 (1) · bintrafusp alfa protein, human (1) · cabozantinib (1) · pazopanib (1) · siremadlin (1)
Centre Leon Berard (1) · Institut Bergonié (1) · Massachusetts General Hospital (1) · Washington University School of Medicine (1)
France (2) · United States (2)
Gregory Cote, M.D. Ph.D (1) · Mia Weiss, M.D. (1)